You can access the annual and quarterly cash flow statements of Alamar Biosciences Ord Shs to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---20.35M
Net income from continuing operations
---21.32M
Operating gains losses
--1.17M
Other non-cash items
--9.73M
Change in working capital
---11.39M
-Change in receivables
---6.85M
-Change in inventory
---1.26M
-Change in prepaid expenses
---1.96M
-Change in other current assets
---327.00K
Cash from non-recurring investing activities
Cash from operating activities
---20.35M
Investing cash flow
Net cash from continuing investing activities
--778.00K
Capital expenditures
--778.00K
Net cash flow from disposal of fixed assets
--600.00K
Net cash flow from intangible asset transactions
--178.00K
Net cash flow from investment products
--0.00
Cash from non-current investing activities
Net cash flow from investing activities
---778.00K
Financing cash flow
Cash flow from continuous financing activities
--55.76M
Net cash flow from debt Issuance/repayment
--56.50M
Proceeds from stock option exercised by employees
--1.80M
Net cash flow from other financing activities
---2.54M
Net cash from non-recurrent financing activities
Net cash from financing activities
--55.76M
Net cash flow
Beginning cash balance
--34.91M
Current period cash flow changes
--34.58M
Effect of exchange rate changes
---52.00K
Ending cash balance
--69.49M
Free cash flow
---21.13M
Currency unit
USD
Audit opinions
--
FAQs
What is the cash flow statement?
This report tracks the movement of cash into and out of the business, covering operating, investing, and financing activities. It highlights how well the company manages cash to support growth and meet its obligations.